This highlights the need to integrate epigenetic markers with conventional biomarkers to refine patient stratification in ICC, a malignancy notoriously resistant to ICIs due to its FGFR2 fusion-driven, immune-cold landscape (3). This evidence concerns the gene FGFR2 and intrahepatic cholangiocarcinoma.